Martin-Broto, Javier
Martinez-Garcia, Jeronimo
Moura, David S.
Redondo, Andres
Gutierrez, Antonio
Lopez-Pousa, Antonio
Martinez-Trufero, Javier http://orcid.org/0000-0002-0997-2573
Sevilla, Isabel
Diaz-Beveridge, Roberto
Solis-Hernandez, Maria Pilar
Carnero, Amancio http://orcid.org/0000-0003-4357-3979
Perez, Marco
Marcilla, David
Garcia-Foncillas, Jesus
Romero, Pablo
Fernandez-Jara, Javier
Lopez-Lopez, Daniel http://orcid.org/0000-0001-7672-7335
Arribas, Ivan
Hindi, Nadia http://orcid.org/0000-0002-5864-762X
Funding for this research was provided by:
Pfizer (NA)
Article History
Received: 12 June 2023
Revised: 6 September 2023
Accepted: 16 September 2023
First Online: 25 October 2023
Competing interests
: J.M.-B. reports research grants from PharmaMar, Eisai, Immix BioPharma, and Novartis outside the submitted work; honoraria for advisory board participation and expert testimony from PharmaMar, Eli Lilly and Company, Bayer, GSK, Novartis, Boehringer Ingelheim, Amgen, Roche, Tecnofarma and Asofarma; and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, BMS, Pfizer, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Celgene, Novartis, Blueprint, Adaptinmune, Nektar, Forma, Amgen, Daichii-Sankyo, Ran Therapeutics, INHIBRX, Ayala Pharmaceuticals, Philogen, Cebiotex, PTC Therapeutics, Inc. and SpringWorks therapeutics. D.S.M. reports institutional research grants from PharmaMar, Eisai, Immix BioPharma, and Novartis outside the submitted work; travel support from PharmaMar, Eisai, Celgene, Bayer and Pfizer, and personal fees from Tecnopharma, outside the submitted work. A.R. reports honoraria and advisory/consultancy (MSD, AstraZeneca, GSK, and PharmaMar); research grant/funding to his institution (Eisai, PharmaMar, and Roche); travel/accommodation/expenses (AstraZeneca, PharmaMar, and Roche); and speakers bureau (MSD, AstraZeneca, GSK, Clovis, and PharmaMar), outside the submitted work. N.H. reports grants, personal fees and non-financial support from PharmaMar, personal fees from Lilly and Tecnopharma, grants from Eisai, and Novartis, outside the submitted work and research funding for clinical studies (institutional) from PharmaMar, Eli Lilly and Company, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Novartis, Blueprint, Nektar, Forma, Amgen and Daichii-Sankyo. The remaining authors declare no competing interests.